This will in my opinion be an institutional investor emerging...

This will in my opinion be an institutional investor emerging from the 'Broker meet Biotech' presentation ANN of 28th May 2015.

Unexpected 'Investor presentations' often precede a CR in Biotech and Mining companies that should have been an eye opener to existing shareholders.

Holmeseath01 good question mate. I probably don't know the answer to that one. A guess would be it is over 15% of issued capital where shareholder approval is required; which also means shareholders can exercise their option to block this CR or ask for a rights issue before the Insto placement.

IMHO; Your thoughts beautiful people !!